Analyzing Benefits and Safety of Darolutamide in mHSPC

Analyzing Benefits and Safety of Darolutamide in mHSPC

During a live event, Jahan Aghalar, MD, discussed the efficacy and safety of darolutamide plus ADT in mHSPC in the ARANOTE trial.

Fitting Oral ADT Options Into the Prostate Cancer Treatment Plans

Panelists discuss how oral androgen deprivation therapy options like relugolix fit into current treatment strategies across multiple patient categories, offering advantages in rapid onset, quick recovery, and convenience, particularly for patients requiring short-term treatment or those with cardiovascular risk factors.